Germ cell tumours articles within Nature Medicine

Featured

• Article
  23 October 2023 | Open Access

  CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

  In the ongoing phase 1/2 BNT211-01 trial, CLDN6-specific chimeric antigen receptor (CAR)-T cells given with or without CARVac, a CAR-T cell-amplifying RNA vaccine, were well-tolerated and exhibited encouraging clinical activity in patients with relapsed or refractory CLDN6-positive solid tumors, with the highest response rate in patients with germ cell tumors.

  • Andreas Mackensen
  • , John B.A.G. Haanen
  •  & Uğur Şahin

• News | 06 December 2010

  Putting stem cells to the test

  To truly know whether a stem cell has the developmental flexibility to give rise to new, therapeutic tissue types, the cells must undergo a definitive test in which they are injected into mice and observed. Yet many say this measure is too slow, too expensive and too unreliable. Elie Dolgin goes in search of a replacement.

  • Elie Dolgin